Table 3.
PD prescription and medication prescription by serum Kprior-4mo
| Serum Kprior4mo, mEq/L |
|||||
|---|---|---|---|---|---|
| <3.5 | 3.5–3.9 | 4.0–4.4 | 4.5–4.9 | ≥5.0 | |
| Patients, n | 823 | 2019 | 2368 | 1555 | 656 |
| PD prescription, % | |||||
| APD | 36 | 65 | 71 | 71 | 68 |
| Wet day (APD) | 51 | 47 | 43 | 41 | 40 |
| Icodextrin | 19 | 34 | 38 | 38 | 40 |
| PD solution glucose concentrations | |||||
| Use of 2.27% but not 3.86% | 32 | 46 | 50 | 47 | 46 |
| Use of any 3.86% | 11 | 17 | 14 | 14 | 15 |
| Without any 2.27% or 3.86% use | 58 | 37 | 36 | 39 | 40 |
| Prescribed volume per BMI, l/(kg/m2), mean (SD) | 0.35 (0.14) | 0.31 (0.16) | 0.29 (0.17) | 0.29 (0.16) | 0.28 (0.16) |
| Prescribed volume per BSA, l/m2, mean (SD) | 4.95 (1.79) | 4.36 (2.21) | 4.15 (2.21) | 4.08 (2.14) | 3.98 (2.12) |
| Medication prescriptions, % | |||||
| RASi (ACEi or ARB) | 38 | 39 | 44 | 52 | 56 |
| Insulin (proportion of diabetic patients only) | 50 | 54 | 53 | 55 | 52 |
| Beta-blocker | 38 | 50 | 52 | 54 | 56 |
| Any diuretic | 55 | 52 | 51 | 51 | 47 |
| Potassium sparing diuretic (aldosterone antagonist) | 4 | 4 | 3 | 3 | 2 |
| Loop diuretic | 53 | 49 | 49 | 49 | 45 |
| Thiazide diuretic | 4 | 6 | 6 | 6 | 6 |
ACEi, angiotensin-converting enzyme inhibitor; APD, automated peritoneal dialysis; ARB, angiotensin II receptor blockers; BMI, body mass index; BSA, body surface area; Kprior-4mo, average monthly serum potassium measured during the 4 months before study enrollment; RASi, renin-angiotensin system inhibition; SD, standard deviation.